<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03008278</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2016-02049</org_study_id>
    <secondary_id>NCI-2016-02049</secondary_id>
    <secondary_id>2000021407</secondary_id>
    <secondary_id>10066</secondary_id>
    <secondary_id>10066</secondary_id>
    <secondary_id>UM1CA186689</secondary_id>
    <nct_id>NCT03008278</nct_id>
  </id_info>
  <brief_title>Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery</brief_title>
  <official_title>A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and best dose of olaparib when given together&#xD;
      with ramucirumab and how well they work in treating patients with gastric or gastroesophageal&#xD;
      junction cancer that has spread to other places in the body (metastatic), has come back&#xD;
      (recurrent), or cannot be removed by surgery (unresectable). Olaparib may stop the growth of&#xD;
      tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with&#xD;
      monoclonal antibodies, such as ramucirumab, may help the body's immune system attack the&#xD;
      cancer, and may interfere with the ability of tumor cells to grow and spread. Giving olaparib&#xD;
      and ramucirumab may work better in treating patients with gastric or gastroesophageal&#xD;
      junction cancer compared to ramucirumab and paclitaxel (a chemotherapy drug) or ramucirumab&#xD;
      alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safe dose of olaparib with ramucirumab, but not to exceed olaparib dose&#xD;
      of 300 mg twice daily (tablet formulation). (Phase I) II. To determine the efficacy of&#xD;
      olaparib plus ramucirumab as measured by the objective response rates (ORR) stratified by&#xD;
      BROCA-HR biomarker status. (Phase II).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate median progression-free survival (PFS) stratified by BROCA-HR biomarker&#xD;
      status.&#xD;
&#xD;
      II. To estimate median overall survival (OS) stratified by BROCA-HR biomarker status.&#xD;
&#xD;
      III. To measure the prevalence of the BROCA-HR biomarker in our study population.&#xD;
&#xD;
      IV. To determine toxicity of olaparib and ramucirumab combination.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To assess the correlation between the signature 3 status, and mutations in BROCA-HR panel.&#xD;
&#xD;
      II. To evaluate the association between findings from BROCA-HR panel with response to&#xD;
      therapy.&#xD;
&#xD;
      III. To evaluate the association between findings from BROCA-HR panel and signature 3 results&#xD;
      with response to therapy.&#xD;
&#xD;
      IV. To determine results of immunoassay for poly-ADP-ribosylated (PAR) substrates in tumor&#xD;
      tissue.&#xD;
&#xD;
      V. To create a PDX model to study deoxyribonucleic acid (DNA) repair in gastric tumors&#xD;
      treated with PARP inhibitors (PARPi) from both pre-treatment biopsy and repeat biopsy after&#xD;
      16 weeks of treatment.&#xD;
&#xD;
      VI. Development of a novel genomic assay for BRCAness. VII. Defining T cell receptor&#xD;
      diversity of gastric cancer patients +/- BRCAness.&#xD;
&#xD;
      VIII. Biobank additional tumor tissue for future genomic analysis. IX. Biobank peripheral&#xD;
      blood for future genomic analysis and assessment of circulating tumor DNA.&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study of olaparib followed by a phase II study.&#xD;
&#xD;
      Patients receive olaparib orally (PO) twice daily (BID) on days 1-14 of each cycle and&#xD;
      ramucirumab intravenously (IV) over 60 minutes on day 1 of each cycle. Cycles repeat every 14&#xD;
      days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 4 weeks and then every 6&#xD;
      weeks thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 6, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity and maximum tolerated dose of olaparib (Phase I)</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Will be assessed by National Cancer Institute (NCI) Common Terminology Criteria (CTCAE) for Adverse Events version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (Phase II)</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Will be defined as complete or partial response assessed by Response Evaluation Criteria in Solid Tumors version 1.1. Will be estimated using the 95% confidence interval (CI) based on Wilson's method. A 5% 2-sided alpha will be used. The Wilcoxon rank sum test and Fisher's exact test will be applied to study the association between the response status and the continuous and categorical variables, respectively. The generalized non-linear model and logistic regression will be applied for multivariable data analysis. The adjusted p-value and 95% CI of the odds ratio will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From start of treatment to time of progression or death, whichever occurs first, assessed up to 6 years</time_frame>
    <description>Will be compared for duration of response survival with Kaplan-Meier estimates and log-rank tests. The Rothman CI will be reported. In addition, the possible risk factors will be compared for survival with log-rank test. For multivariate analysis, the proportional hazards Cox model will be applied to investigate potential prognostic factors, such as age and stage of disease of the PFS data. The adjusted p-values of the hazard ratios and the adjusted 95% confidence interval will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Will be compared for duration of response survival with Kaplan-Meier estimates and log-rank tests. The Rothman CI will be reported. In addition, the possible risk factors will be compared for survival with log-rank test. The adjusted p-values of the hazard ratios and the adjusted 95% confidence interval will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BROCA-HR status</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Will be compared for duration of response survival with Kaplan-Meier estimates and log-rank tests. The Rothman CI will be reported. In addition, the possible risk factors will be compared for survival with log-rank test. The adjusted p-values of the hazard ratios and the adjusted 95% confidence interval will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 30 days of last dose administration</time_frame>
    <description>Will be assessed by NCI CTCAE version 5.0. Will be tabulated by type and grade and compared to established rates for ramucirumab monotherapy. Ninety-five percent confidence intervals will be calculated for each of these.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>BROCA HR assay</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>The association of BROCA HR assay with Signature 3 will be assessed using a series of contingency table analyses. The association of the presence of an individual mutation from the BROCA HR panel with the signature 3 (yes/no) using Fisher's exact test. Using a Cochran Mantel Haenzel test the relationship across all three measures will be examined. Finally, the relationship of each of these measures with response will be examined. To do this multiple logistic regression models can be fit with the response (complete response/partial response vs stable disease/partial disease) considered as the outcome variable and the assay measures can be used predictors.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tumor cells for PDX model, and biobanked tumor tissue and peripheral blood</measure>
    <time_frame>Up to 6 years</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Metastatic Esophageal Carcinoma</condition>
  <condition>Metastatic Gastric Carcinoma</condition>
  <condition>Metastatic Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Recurrent Esophageal Carcinoma</condition>
  <condition>Recurrent Gastric Carcinoma</condition>
  <condition>Recurrent Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Stage III Esophageal Cancer AJCC v7</condition>
  <condition>Stage III Gastric Cancer AJCC v7</condition>
  <condition>Stage IV Esophageal Cancer AJCC v7</condition>
  <condition>Stage IV Gastric Cancer AJCC v7</condition>
  <condition>Unresectable Esophageal Carcinoma</condition>
  <condition>Unresectable Gastric Carcinoma</condition>
  <condition>Unresectable Gastroesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (olaparib, ramucirumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive olaparib PO BID on days 1-14 of each cycle and ramucirumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>Give PO</description>
    <arm_group_label>Treatment (olaparib, ramucirumab)</arm_group_label>
    <other_name>AZD 2281</other_name>
    <other_name>AZD-2281</other_name>
    <other_name>AZD2281</other_name>
    <other_name>KU-0059436</other_name>
    <other_name>Lynparza</other_name>
    <other_name>Olanib</other_name>
    <other_name>Olaparix</other_name>
    <other_name>PARP Inhibitor AZD2281</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (olaparib, ramucirumab)</arm_group_label>
    <other_name>Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B</other_name>
    <other_name>Cyramza</other_name>
    <other_name>IMC-1121B</other_name>
    <other_name>LY3009806</other_name>
    <other_name>Monoclonal Antibody HGS-ETR2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must have histologically confirmed, gastric carcinoma, including&#xD;
             gastroesophageal junction (GEJ) adenocarcinoma (patients with adenocarcinoma of the&#xD;
             distal esophagus are eligible if the primary tumor involves the GEJ)&#xD;
&#xD;
          -  The patient has metastatic disease or locally recurrent, unresectable disease&#xD;
&#xD;
          -  The patient must have measurable disease by Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST) version (v)1.1&#xD;
&#xD;
          -  The patient must have experienced disease progression during or within 4 months after&#xD;
             the last dose of chemotherapy for metastatic disease, during or within 6 months after&#xD;
             the last dose of adjuvant chemotherapy, or have been intolerant of previous&#xD;
             chemotherapy&#xD;
&#xD;
          -  The patient must have experienced disease progression or intolerance as outlined above&#xD;
             after treatment with 1 or more prior chemotherapies&#xD;
&#xD;
          -  All previous treatments are acceptable as long as they did not contain bevacizumab,&#xD;
             ramucirumab or PARP inhibitors&#xD;
&#xD;
          -  Elevation in tumor markers without radiographic evidence of disease progression is not&#xD;
             satisfactory for progression on previous treatment&#xD;
&#xD;
          -  The patient is &gt;= 18 years of age&#xD;
&#xD;
          -  The patient has a life expectancy of &gt;= 16 weeks&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 (Karnofsky&#xD;
             &gt;= 60%)&#xD;
&#xD;
          -  Hemoglobin &gt;= 10 g/dL with no blood transfusions (packed red blood cells and platelet&#xD;
             transfusions) in the past 28 days (within 28 days prior to administration of study&#xD;
             treatment)&#xD;
&#xD;
          -  White blood cells (WBC) &gt; 3 x 10^9/L (within 28 days prior to administration of study&#xD;
             treatment)&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1.5 10^9/L (within 28 days prior to administration&#xD;
             of study treatment)&#xD;
&#xD;
          -  Platelet count &gt;= 100 X 10^9/L (within 28 days prior to administration of study&#xD;
             treatment)&#xD;
&#xD;
          -  No features suggestive of myelodysplastic syndrome (MDS)/acute myelogenous leukemia&#xD;
             (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated (within&#xD;
             28 days prior to administration of study treatment)&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x the institutional upper limit of normal (ULN) (within 28 days&#xD;
             prior to administration of study treatment)&#xD;
&#xD;
          -  Aspartate aminotransferases (AST) (serum glutamic-oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 2.5 x institutional ULN unless liver metastases are present in which case they must&#xD;
             be =&lt; 5 x ULN (within 28 days prior to administration of study treatment)&#xD;
&#xD;
          -  Calculated serum creatinine clearance &gt;= 60 mL/min/1.73 m^2 (within 28 days prior to&#xD;
             administration of study treatment)&#xD;
&#xD;
          -  Proteinuria with urinary protein =&lt; 1+ on dipstick or routine urinalysis, or a 24-hour&#xD;
             urine collection for protein &lt; 1000 mg of protein in 24 hours (within 28 days prior to&#xD;
             administration of study treatment)&#xD;
&#xD;
          -  Coagulation parameters (international normalized ratio [INR], activated partial&#xD;
             thromboplastin time [aPTT]) =&lt; 1.25 x institutional limits, except where a lupus&#xD;
             anti-coagulant has been confirmed or the patient is on warfarin; patients on full dose&#xD;
             anticoagulation must be on a stable dose for at least 14 days; if receiving warfarin,&#xD;
             the patient must have an INR =&lt; 3.0 without any evidence of active bleeding within 14&#xD;
             days prior to first dose of study treatment or a pathologic condition that carries a&#xD;
             high risk of bleeding (tumor involvement with major blood vessels or varices) (within&#xD;
             28 days prior to administration of study treatment)&#xD;
&#xD;
          -  Postmenopausal or evidence of non-childbearing status for women of childbearing&#xD;
             potential a negative urine or serum pregnancy test within 28 days of study treatment&#xD;
             and confirmed prior to treatment on day 1; postmenopausal is defined as:&#xD;
&#xD;
               -  Amenorrheic for 1 year or more following cessation of exogenous hormonal&#xD;
                  treatments&#xD;
&#xD;
               -  Luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the&#xD;
                  postmenopausal range for women under 50&#xD;
&#xD;
               -  Radiation-induced oophorectomy with last menses &gt; 1 year ago&#xD;
&#xD;
               -  Chemotherapy-induced menopause with &gt; 1 year interval since last menses&#xD;
&#xD;
               -  Surgical sterilization (bilateral oophorectomy or hysterectomy)&#xD;
&#xD;
          -  The effects of olaparib and ramucirumab on the developing fetus are unknown; for this&#xD;
             reason, women of child-bearing potential and men must agree to use adequate&#xD;
             contraception including hormonal, barrier, or abstinence; contraception must be&#xD;
             started prior to study enrollment; female patients of childbearing potential must have&#xD;
             a negative serum pregnancy test within 7 days prior to treatment; should a woman&#xD;
             become pregnant or suspect she is pregnant while she or her partner is participating&#xD;
             in this study, she should inform her treating physician immediately; both men and&#xD;
             women treated or enrolled on this protocol must also agree to use adequate&#xD;
             contraception prior to the study, for the duration of the study participation, and for&#xD;
             3 months after completion of olaparib and ramucirumab administration; male patients&#xD;
             and their partners, who are sexually active and of childbearing potential, must agree&#xD;
             to the use of two highly effective forms of contraception in combination, throughout&#xD;
             the period of taking study treatment and for 3 months after last dose of study drug(s)&#xD;
             to prevent pregnancy in a partner&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          -  The patient must be willing to undergo a biopsy prior to treatment, an on treatment&#xD;
             biopsy at week 16 is optional if felt to be safe in the opinion of the investigator&#xD;
&#xD;
          -  For inclusion into optional exploratory genetic and biomarker research, patients must&#xD;
             fulfill the following criteria:&#xD;
&#xD;
               -  Provision of informed consent for genetic research&#xD;
&#xD;
               -  Provision of informed consent for biomarker research&#xD;
&#xD;
                    -  If a patient declines to participate in the optional exploratory genetic&#xD;
                       research or the optional biomarker research, there will be no penalty or&#xD;
                       loss of benefit to the patient; the patient will not be excluded from other&#xD;
                       parts of the study&#xD;
&#xD;
          -  Patients must be able to tolerate oral medications by mouth, and not have a&#xD;
             gastrointestinal illness that would preclude absorption of olaparib&#xD;
&#xD;
          -  Adequately controlled blood pressure (BP) &lt; 140 mmHg (systolic) and &lt; 90 mmHg&#xD;
             (diastolic) taken in the clinic setting by a medical professional within 2 weeks prior&#xD;
             to starting study; patients with hypertension may be managed with up to a maximum of 3&#xD;
             antihypertensive medications; a cardiologist or blood pressure specialist must&#xD;
             evaluate patients who are on 3 antihypertensive medications within 4 weeks of&#xD;
             enrollment&#xD;
&#xD;
          -  Patients who have the following risk factors are considered to be at increased risk&#xD;
             for cardiac toxicity and must have documented left ventricular ejection fraction&#xD;
             (LVEF) by echocardiogram greater than institution's lower limit of normal (or 55% if&#xD;
             threshold for normal not otherwise specified by institutional guidelines) obtained&#xD;
             within 3 months&#xD;
&#xD;
               -  Prior treatment with anthracyclines&#xD;
&#xD;
               -  Prior treatment with trastuzumab&#xD;
&#xD;
               -  A New York Heart Association (NYHA) classification of II controlled with&#xD;
                  treatment&#xD;
&#xD;
               -  Prior central thoracic radiation therapy (RT), including RT to the heart&#xD;
&#xD;
               -  History of myocardial infarction within 12 months (patients with history of&#xD;
                  myocardial infarction within 6 months are excluded)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with untreated brain metastases are excluded from this clinical trial because&#xD;
             of their poor prognosis and because they often develop progressive neurologic&#xD;
             dysfunction that would confound the evaluation of neurologic and other adverse events;&#xD;
             a scan to confirm the absence of brain metastases is not required; the patient can&#xD;
             receive a stable dose of corticosteroids before and during the study as long as these&#xD;
             were started at least 4 weeks prior to treatment; patients with spinal cord&#xD;
             compression are also excluded unless considered to have received definitive treatment&#xD;
             for this and evidence of clinically stable disease for 28 days&#xD;
&#xD;
          -  Patients who have not recovered from adverse events due to prior anti-cancer therapy&#xD;
             (i.e., have residual toxicities &gt; Common Terminology Criteria for Adverse Events&#xD;
             [CTCAE] grade 1 or baseline, with the exception of alopecia)&#xD;
&#xD;
          -  Patients unable to swallow orally administered medication and patients with&#xD;
             gastrointestinal disorders likely to interfere with absorption of the study medication&#xD;
&#xD;
          -  The patient has experienced any grade 3-4 gastrointestinal bleeding within 3 months&#xD;
             prior to randomization&#xD;
&#xD;
          -  The patient has experienced any arterial thrombotic events, including but not limited&#xD;
             to myocardial infarction, transient ischemic attack, cerebrovascular accident, or&#xD;
             unstable angina, within 6 months prior to enrollment&#xD;
&#xD;
          -  The patient has an ongoing or active infection, symptomatic congestive heart failure,&#xD;
             unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia,&#xD;
             uncontrolled thrombotic or hemorrhagic disorder, or any other serious uncontrolled&#xD;
             medical disorder in the opinion of the investigator&#xD;
&#xD;
          -  The patient has an ongoing or active psychiatric illness or social situation that&#xD;
             would limit compliance with study requirements&#xD;
&#xD;
          -  Clinically significant peripheral vascular disease or vascular disease (abdominal&#xD;
             aortic aneurysm &gt; 5 cm) or aortic dissection; if known history of abdominal aortic&#xD;
             aneurysm with &gt;= 4 cm in diameter, all of the following must be met&#xD;
&#xD;
               -  An ultrasound within the last 6 months required to document that it is =&lt; 5 cm&#xD;
&#xD;
               -  Patient must be asymptomatic from the aneurysm&#xD;
&#xD;
               -  Blood pressure must be well controlled as defined in this protocol&#xD;
&#xD;
          -  The patient has uncontrolled or poorly controlled hypertension despite standard&#xD;
             medical management as defined in this protocol&#xD;
&#xD;
          -  NYHA classification of III or IV&#xD;
&#xD;
          -  A resting electrocardiogram (EKG) with a corrected QT (QTC) &gt;= 470 msec detected on 2&#xD;
             or more time points within a 2 hour period or family history of long QT syndrome; if&#xD;
             the EKG demonstrates QTC &gt;= 470 msec, the patient will only be eligible if a repeat&#xD;
             EKG demonstrates QTC =&lt; 470 msec&#xD;
&#xD;
          -  History of hypertensive crisis or hypertensive encephalopathy within 3 years&#xD;
&#xD;
          -  Major surgery within 28 days of starting study treatment and patients must have&#xD;
             recovered from any effects of any major surgery&#xD;
&#xD;
          -  An open biopsy, non-healing wound, ulcer or significant traumatic injury within 28&#xD;
             days prior to starting treatment (percutaneous, endobronchial, and endoscopic biopsies&#xD;
             are allowed)&#xD;
&#xD;
          -  The patient has received chemotherapy, radiotherapy (except for palliative reasons),&#xD;
             immunotherapy, or targeted therapy for gastric cancer within 3 weeks of study&#xD;
             treatment&#xD;
&#xD;
          -  The patient has received any investigational therapy within 4 weeks of enrollment&#xD;
&#xD;
          -  The patient has received prior therapy with bevacizumab, ramucirumab or any PARP&#xD;
             inhibitor, including olaparib&#xD;
&#xD;
          -  Patients must not have evidence of coagulopathy or bleeding diathesis; therapeutic&#xD;
             anticoagulation for prior thromboembolic events is permitted; the clinical indication&#xD;
             for therapeutic anticoagulation must be clearly documented prior to enrollment and&#xD;
             must be discussed with the principal investigator (PI); due to risk of serious&#xD;
             bleeding with ramucirumab, patients on greater than or equal to 2 anti-thrombotic&#xD;
             agents, including but not limited to anti-platelet agents (nonsteroidal&#xD;
             anti-inflammatory drugs [NSAIDS]/aspirin, clopidogrel), heparin, low molecular weight&#xD;
             heparin, warfarin and a direct thrombin inhibitor will be excluded&#xD;
&#xD;
          -  The patient has elective or planned major surgery to be performed during the course of&#xD;
             the clinical trial&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to olaparib and ramucirumab&#xD;
&#xD;
          -  Patients with a known hypersensitivity to olaparib or any of the excipients of the&#xD;
             product&#xD;
&#xD;
          -  Patients with a known hypersensitivity to the combination/comparator agent&#xD;
&#xD;
          -  Pregnant or breast feeding women are excluded from this study because olaparib and&#xD;
             ramucirumab have the potential for teratogenic or abortifacient effects&#xD;
&#xD;
          -  Immunocompromised patients, this includes human immunodeficiency virus (HIV)-positive&#xD;
             patients, because of the potential for interaction with antiretroviral therapy and&#xD;
             ramucirumab and/or olaparib; in addition, these patients are at increased risk of&#xD;
             lethal infections when treated with marrow-suppressive therapy&#xD;
&#xD;
          -  Patients with a known history of hepatitis B (defined as hepatitis B surface antigen&#xD;
             [HBsAg] reactive) or known active hepatitis C virus (defined as detectable hepatitis C&#xD;
             virus [HCV] ribonucleic acid [RNA]) infection; Note: no testing for hepatitis B and&#xD;
             hepatitis C is required unless mandated by local health authority&#xD;
&#xD;
          -  The patient has known and active alcohol or drug dependency&#xD;
&#xD;
          -  The patient has a concurrent active malignancy other than treated non-melanoma skin&#xD;
             cancers or in situ neoplasm; a patient with a prior history of malignancy is eligible,&#xD;
             provided that they have been free of disease for &gt;= 5 years&#xD;
&#xD;
          -  Patients may not have features suggestive of myelodysplastic syndrome (MDS) or acute&#xD;
             myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if&#xD;
             clinically indicated&#xD;
&#xD;
          -  Patients may not have had a prior allogeneic bone marrow transplant or double&#xD;
             umbilical cord blood transplantation (dUCBT)&#xD;
&#xD;
          -  Patients may not have current signs and/or symptoms of bowel obstruction within 1&#xD;
             month prior to starting study drugs, except if it was a temporary incident (improved&#xD;
             within &lt; 24 hours [hr] with medical management)&#xD;
&#xD;
          -  History of hemoptysis within the last 1 month&#xD;
&#xD;
          -  History of abdominal fistula, intra-abdominal abscess, or gastrointestinal perforation&#xD;
             within the last 3 months&#xD;
&#xD;
          -  Dependency on IV hydration &gt; 1 day per week within the screening period&#xD;
&#xD;
          -  Participants receiving any medications or substances that are strong inhibitors or&#xD;
             inducers of CYP3A4/5 are ineligible; the required washout period prior to starting&#xD;
             treatment is 2 weeks for CYP3A inhibitors, 3 weeks for CYP3A inducers, and 5 weeks for&#xD;
             enzalutamide; dihydropyridine calcium-channel blockers are permitted for management of&#xD;
             hypertension&#xD;
&#xD;
          -  Whole blood transfusions in the last 120 days prior to entry to the study (packed red&#xD;
             blood cells and platelet transfusions are acceptable)&#xD;
&#xD;
          -  Involvement in the planning and/or conduct of the study (applies to both AstraZeneca&#xD;
             staff and/or staff at the study site)&#xD;
&#xD;
          -  Previous enrollment in the present study&#xD;
&#xD;
          -  Current use of natural herb products or other complementary alternative medications;&#xD;
             if used previously, patients must have at least 1-week washout and must stop using&#xD;
             them while participating in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Cecchini</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University Cancer Center LAO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Corona</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92879</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Antelope Valley</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mount Zion</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope South Pasadena</name>
      <address>
        <city>South Pasadena</city>
        <state>California</state>
        <zip>91030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Upland</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital-Derby Care Center</name>
      <address>
        <city>Derby</city>
        <state>Connecticut</state>
        <zip>06418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital Care Center-Fairfield</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital Care Center - Guilford</name>
      <address>
        <city>Guilford</city>
        <state>Connecticut</state>
        <zip>06437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital Care Center at Saint Francis</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Center/Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale-New Haven Hospital North Haven Medical Center</name>
      <address>
        <city>North Haven</city>
        <state>Connecticut</state>
        <zip>06473</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital-Orange Care Center</name>
      <address>
        <city>Orange</city>
        <state>Connecticut</state>
        <zip>06477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital-Torrington Care Center</name>
      <address>
        <city>Torrington</city>
        <state>Connecticut</state>
        <zip>06790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital Care Center-Trumbull</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital-Waterbury Care Center</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital Care Center - Waterford</name>
      <address>
        <city>Waterford</city>
        <state>Connecticut</state>
        <zip>06385</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Science Center - Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weisberg Cancer Treatment Center</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute (UPCI)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Breast Center at One Hundred Oaks</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2023</verification_date>
  <study_first_submitted>December 30, 2016</study_first_submitted>
  <study_first_submitted_qc>December 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2017</study_first_posted>
  <last_update_submitted>September 12, 2023</last_update_submitted>
  <last_update_submitted_qc>September 12, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Poly(ADP-ribose) Polymerase Inhibitors</mesh_term>
    <mesh_term>Ramucirumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Lexatumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03008278
org study id: NCI-2016-02049
secondary id: NCI-2016-02049
secondary id: 2000021407
secondary id: 10066
secondary id: 10066
secondary id: UM1CA186689
nct id: NCT03008278
lead sponsor: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
This phase I/II trial studies the side effects and best dose of olaparib when given together
      with ramucirumab and how well they work in treating patients with gastric or gastroesophageal
      junction cancer that has spread to other places in the body (metastatic), has come back
      (recurrent), or cannot be removed by surgery (unresectable). Olaparib may stop the growth of
      tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with
      monoclonal antibodies, such as ramucirumab, may help the body's immune system attack the
      cancer, and may interfere with the ability of tumor cells to grow and spread. Giving olaparib
      and ramucirumab may work better in treating patients with gastric or gastroesophageal
      junction cancer compared to ramucirumab and paclitaxel (a chemotherapy drug) or ramucirumab
      alone.
PRIMARY OBJECTIVES:

      I. To determine the safe dose of olaparib with ramucirumab, but not to exceed olaparib dose
      of 300 mg twice daily (tablet formulation). (Phase I) II. To determine the efficacy of
      olaparib plus ramucirumab as measured by the objective response rates (ORR) stratified by
      BROCA-HR biomarker status. (Phase II).

      SECONDARY OBJECTIVES:

      I. To estimate median progression-free survival (PFS) stratified by BROCA-HR biomarker
      status.

      II. To estimate median overall survival (OS) stratified by BROCA-HR biomarker status.

      III. To measure the prevalence of the BROCA-HR biomarker in our study population.

      IV. To determine toxicity of olaparib and ramucirumab combination.

      EXPLORATORY OBJECTIVES:

      I. To assess the correlation between the signature 3 status, and mutations in BROCA-HR panel.

      II. To evaluate the association between findings from BROCA-HR panel with response to
      therapy.

      III. To evaluate the association between findings from BROCA-HR panel and signature 3 results
      with response to therapy.

      IV. To determine results of immunoassay for poly-ADP-ribosylated (PAR) substrates in tumor
      tissue.

      V. To create a PDX model to study deoxyribonucleic acid (DNA) repair in gastric tumors
      treated with PARP inhibitors (PARPi) from both pre-treatment biopsy and repeat biopsy after
      16 weeks of treatment.

      VI. Development of a novel genomic assay for BRCAness. VII. Defining T cell receptor
      diversity of gastric cancer patients +/- BRCAness.

      VIII. Biobank additional tumor tissue for future genomic analysis. IX. Biobank peripheral
      blood for future genomic analysis and assessment of circulating tumor DNA.

      OUTLINE: This is a phase I, dose-escalation study of olaparib followed by a phase II study.

      Patients receive olaparib orally (PO) twice daily (BID) on days 1-14 of each cycle and
      ramucirumab intravenously (IV) over 60 minutes on day 1 of each cycle. Cycles repeat every 14
      days in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 4 weeks and then every 6
      weeks thereafter.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Dose limiting toxicity and maximum tolerated dose of olaparib (Phase I)
time frame: Up to 14 days
description: Will be assessed by National Cancer Institute (NCI) Common Terminology Criteria (CTCAE) for Adverse Events version 5.0.
measure: Objective response rate (Phase II)
time frame: Up to 6 years
description: Will be defined as complete or partial response assessed by Response Evaluation Criteria in Solid Tumors version 1.1. Will be estimated using the 95% confidence interval (CI) based on Wilson's method. A 5% 2-sided alpha will be used. The Wilcoxon rank sum test and Fisher's exact test will be applied to study the association between the response status and the continuous and categorical variables, respectively. The generalized non-linear model and logistic regression will be applied for multivariable data analysis. The adjusted p-value and 95% CI of the odds ratio will be reported.
measure: Progression free survival
time frame: From start of treatment to time of progression or death, whichever occurs first, assessed up to 6 years
description: Will be compared for duration of response survival with Kaplan-Meier estimates and log-rank tests. The Rothman CI will be reported. In addition, the possible risk factors will be compared for survival with log-rank test. For multivariate analysis, the proportional hazards Cox model will be applied to investigate potential prognostic factors, such as age and stage of disease of the PFS data. The adjusted p-values of the hazard ratios and the adjusted 95% confidence interval will be reported.
measure: Overall survival
time frame: Up to 6 years
description: Will be compared for duration of response survival with Kaplan-Meier estimates and log-rank tests. The Rothman CI will be reported. In addition, the possible risk factors will be compared for survival with log-rank test. The adjusted p-values of the hazard ratios and the adjusted 95% confidence interval will be reported.
measure: BROCA-HR status
time frame: Up to 6 years
description: Will be compared for duration of response survival with Kaplan-Meier estimates and log-rank tests. The Rothman CI will be reported. In addition, the possible risk factors will be compared for survival with log-rank test. The adjusted p-values of the hazard ratios and the adjusted 95% confidence interval will be reported.
measure: Incidence of adverse events
time frame: Up to 30 days of last dose administration
description: Will be assessed by NCI CTCAE version 5.0. Will be tabulated by type and grade and compared to established rates for ramucirumab monotherapy. Ninety-five percent confidence intervals will be calculated for each of these.
measure: BROCA HR assay
time frame: Up to 6 years
description: The association of BROCA HR assay with Signature 3 will be assessed using a series of contingency table analyses. The association of the presence of an individual mutation from the BROCA HR panel with the signature 3 (yes/no) using Fisher's exact test. Using a Cochran Mantel Haenzel test the relationship across all three measures will be examined. Finally, the relationship of each of these measures with response will be examined. To do this multiple logistic regression models can be fit with the response (complete response/partial response vs stable disease/partial disease) considered as the outcome variable and the assay measures can be used predictors.
measure: Tumor cells for PDX model, and biobanked tumor tissue and peripheral blood
time frame: Up to 6 years
arm group label: Treatment (olaparib, ramucirumab)
arm group type: Experimental
description: Patients receive olaparib PO BID on days 1-14 of each cycle and ramucirumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
intervention type: Drug
intervention name: Olaparib
description: Give PO
arm group label: Treatment (olaparib, ramucirumab)
other name: AZD 2281
other name: AZD-2281
other name: AZD2281
other name: KU-0059436
other name: Lynparza
other name: Olanib
other name: Olaparix
other name: PARP Inhibitor AZD2281
intervention type: Biological
intervention name: Ramucirumab
description: Given IV
arm group label: Treatment (olaparib, ramucirumab)
other name: Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B
other name: Cyramza
other name: IMC-1121B
other name: LY3009806
other name: Monoclonal Antibody HGS-ETR2
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Michael Cecchini
role: Principal Investigator
affiliation: Yale University Cancer Center LAO
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: United States
responsible party type: Sponsor
mesh term: Carcinoma
mesh term: Adenocarcinoma
mesh term: Stomach Neoplasms
mesh term: Esophageal Neoplasms
mesh term: Recurrence
mesh term: Antineoplastic Agents, Immunological
mesh term: Olaparib
mesh term: Poly(ADP-ribose) Polymerase Inhibitors
mesh term: Ramucirumab
mesh term: Antibodies
mesh term: Immunoglobulins
mesh term: Antibodies, Monoclonal
mesh term: Lexatumumab